Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com
by Kim Johansen · The Markets DailyStockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
NASDAQ:AEZS opened at $3.70 on Monday. Aeterna Zentaris has a twelve month low of $3.96 and a twelve month high of $12.00. The stock’s 50-day simple moving average is $4.65 and its 200 day simple moving average is $6.29. The firm has a market capitalization of $6.63 million, a PE ratio of -0.25 and a beta of 1.55.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than Aeterna Zentaris
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Momentum Trades for October With Ample Upside Ahead
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- How to Invest in Insurance Companies: A Guide
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice